Day 1 articles

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read article Magnus Ohman2012-08-25

Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure Treatment

Editorial Comment: Fifty per cent of all HF patients involves Diastolic Heart Failure or HF with conserved ventricular function. This study aimed at evaluating the efficacy and safety of 25mg spironolactone after a year of therapy. Results showed improved diastolic function, induced structural inverse remodelling, reduced neuroendocrine activation and reduced blood pressure (effects on cardiac

PURE: This study shows different patterns of cardiovascular risk factor prevalence in countries with different socio-economical background, and recommends individualized intervention..

Presentation Summary: The Prospective Urban Rural Epidemiologic (PURE) study evaluated 153996 people from different countries and different socioeconomic background. Tobacco consumption, physical activity and nutritional aspects were analyzed. Researchers found that meat consumption, industrialized products and saturated fat rates were more elevated in developed countries, while developing countries showed higher levels of carbohydrates consumption. Developing

ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using Cardio Renal Endpoints.

Editorial Comment: Morbimortality in diabetic patients is still a matter of deep concern in the context of reduced cardiovascular mortality of recent years. Based on the proven clinical benefit of drugs such as ACEIs or ARBs in treating patients with renal failure, the study randomized 8700 treated with aliskiren or placebo, in a 32 month

PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .

Editorial Comment: This Phase II study included 149 patients following these criteria: NYHA II-IV heart failure, +40 yr, LVEF ≥ 45% NT-proBNP> 400 pg/ml. The study aimed at reducing NT-proBNP from baseline at 12 weeks. Results were positive; reduced left atrial size and an improvement in NYHA class were also observed. The drug was well

Top